Human Reproduction, Vol. 17, No. 2, 289-294,
February 2002
© 2002 European Society of Human Reproduction and Embryology
Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial
lu3it11 Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, 2 Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine, Hacettepe University and 3 Department of Obstetrics and Gynecology, Faculty of Medicine, Basikent University and 4 Department of Nuclear Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
BACKGROUND: This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance. METHODS AND RESULTS: Thirty-two patients were randomized to metformin (n = 16) and placebo (n = 16) groups. Hormonal assessment, a 75 g oral glucose tolerance test (OGTT) and a frequently sampled i.v. glucose tolerance test (FSIGTT) were performed before and after oral administration of metformin (850 mg twice daily) or placebo for 6 weeks. Recombinant FSH treatment was undertaken, thereafter, in women who did not ovulate on metformin (n = 10) or placebo (n = 15). There was no significant change in all insulin sensitivity indices in both groups. The only change noted was a decline in mean serum free testosterone concentration in the metformin group (P = 0.049). One patient on placebo and six patients on metformin ovulated spontaneously (P < 0.05). All parameters of ovarian response were comparable between the two groups during rFSH treatment. Combining the 6 week placebo or metformin-only period with a single rFSH treatment cycle, the overall ovulation rates were 75 and 94% in the placebo and metformin groups respectively (P > 0.05). The respective figures for pregnancy were 6.3 and 31.3% (P > 0.05). CONCLUSIONS: Metformin may restore ovulation with no improvement on insulin resistance in clomiphene citrate-resistant PCOS patients with normal glucose tolerance, but has no significant effect on ovarian response during rFSH treatment.
Key words: insulin resistance/low-dose step-up protocol/metformin/polycystic ovary syndrome/rFSH
5 To whom correspondence should be addressed at: Hafta sokak, No. 23/4, Gaziosmanpasia 06700 Ankara, Turkey. E-mail: hyarali{at}hacettepe.edu.tr or yarali{at}ada.net.tr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Moll, F. van der Veen, and M. van Wely The role of metformin in polycystic ovary syndrome: a systematic review Hum. Reprod. Update, November 1, 2007; 13(6): 527 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dias, R. McNamee, and A. Vail Evidence of improving quality of reporting of randomized controlled trials in subfertility Hum. Reprod., October 1, 2006; 21(10): 2617 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Costello, M. Chapman, and U. Conway A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome Hum. Reprod., June 1, 2006; 21(6): 1387 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tang, J. Glanville, N. Orsi, J. H. Barth, and A. H. Balen The use of metformin for women with PCOS undergoing IVF treatment Hum. Reprod., June 1, 2006; 21(6): 1416 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Palomba, A. Falbo, F. Orio Jr, F. Manguso, T. Russo, A. Tolino, C. Annamaria, B. Dale, and F. Zullo A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination Hum. Reprod., October 1, 2005; 20(10): 2879 - 2886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J P van Santbrink, F. P Hohmann, M. J C Eijkemans, J. S E Laven, and B. C J M Fauser Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment Eur. J. Endocrinol., April 1, 2005; 152(4): 611 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.S. Sonmez, L. Yasar, K. Savan, S. Koc, J. Ozcan, A. Toklar, F. Yazicioglu, A. Akgun, and N. Sut Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome Hum. Reprod., January 1, 2005; 20(1): 175 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kashyap, G. A. Wells, and Z. Rosenwaks Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome Hum. Reprod., November 1, 2004; 19(11): 2474 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, F. Orio Jr., L. G. Nardo, A. Falbo, T. Russo, D. Corea, P. Doldo, G. Lombardi, A. Tolino, A. Colao, et al. Metformin Administration Versus Laparoscopic Ovarian Diathermy in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome: A Prospective Parallel Randomized Double-Blind Placebo-Controlled Trial J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4801 - 4809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.B. Kjotrod, V. von During, and S.M. Carlsen Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study Hum. Reprod., June 1, 2004; 19(6): 1315 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Lord, I. H K Flight, and R. J Norman Metformin in polycystic ovary syndrome: systematic review and meta-analysis BMJ, October 25, 2003; 327(7421): 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. M Ahmed Polycystic ovaries: treatment strategies Perspectives in Public Health, September 1, 2003; 123(3): 152 - 153. [PDF]
|
|
|
|
|
|
L. A. Stadtmauer, B. C. Wong, and S. Oehninger Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yarali and B. Yildiz Metformin and FSH for induction of ovulation in women with polycystic ovary syndrome Hum. Reprod., November 1, 2002; 17(11): 3007 - 3008. [Full Text] [PDF]
|
|
|
|
|
|
V. De Leo and A. la Marca Metformin and FSH for induction of ovulation in women with polycystic ovarian syndrome Hum. Reprod., September 1, 2002; 17(9): 2481 - 2482. [Full Text] [PDF]
|
|